Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 15/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164410 | 0.91 | ALDH1A1 (0.40) | ALDH1A1NPC1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL7159960 | 0.89 | ALDH1A1 (0.39) | ALDH1A1NPC1ABCB1SLC43A1 | |
| SCHEMBL7038066 | 0.88 | MEN1 (0.41) | ALDH1A1CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL7161159 | 0.87 | ALDH1A1 (0.39) | ALDH1A1NPC1ABCB1 | |
| SCHEMBL7038041 | 0.83 | UPP1 (0.39) | ALDH1A1CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL14615902 | 0.83 | ALDH1A1 (0.44) | ALDH1A1NPC1ABCB1SLC43A1 | |
| SCHEMBL7035707 | 0.83 | POLB (0.36) | ALDH1A1CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL30008148 | 0.82 | ALDH1A1 (0.41) | ALDH1A1NPC1ABCB1CHRNB2CHRNA5 | |
| SCHEMBL7037404 | 0.81 | HPGD (0.40) | ALDH1A1NPC1CHRNB2CHRNA5CHRNA7 | |
| SCHEMBL12111919 | 0.81 | ALDH1A1 (0.44) | ALDH1A1NPC1ABCB1SLC43A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | disclosed |
| EP-0747389-B1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-RE38090-E1 | Antitumor activity; useful for treatment and prevention of cancers | Matsuda, Akira (JP) | 2003-04-22 | — | — | US | disclosed |
| US-5763418-A | NUCLEOTIDE ANTITUMOR AGENTS | Matsuda, Akira (JP) | 1998-06-09 | — | — | US | disclosed |
| EP-0747389-A1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | TYMP, MTAP, GART | ALDH1A1 3050/4885NPC1 4787/4885ABCB1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.